• Contact us
  • E-Submission
ABOUT
BROWSE ARTICLES
JOURNAL POLICIES
FOR CONTRIBUTORS

Articles

Page Path

Original Article

Endothelin-1 In Patients With Lupus Nephritis

The Ewha Medical Journal 1993;16(3):215-226. Published online: July 24, 2015

Department of Internal Medicine, College of Medicine, Ewha Womans University, Korea.

Copyright © 1993. Ewha Womans University School of Medicine

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 32 Views
  • 0 Download
next
  • Endothelin is a 21-residue peptide vasoconstrictor produced by endothelium. The exact role of endothelin in the pathophysiology of renal disease has not yet been extensively demonstrated. Thus, to elucidate the pathophysiological significance of plasma and urinary endothelin-1 (ET-1) in patients with lupus nephritis. we studied 7 patients diagnosed as lupus nephritis by kidney biopsy and 7 healthy volunteers. Serum and urinary biochemical studies including creatinine and ET-1 were done, and urinary excretion of N-acetyl-β-D-glucosaminidase(NAG) was also measured.
    The results were as follows ;
    1) Patient poop and control group showed no significant differences in their clinical characteristics, basic biochemical studies, serum creatinine, plasma ET-1, urinary excretion of protein. NAG and creatinine and ET-1 clearance. Of 7 lupus nephritis patients, only 2 patients showed abnormal serum complement and anti-dsDNA.
    2) In lupus nephritis patients, plasma ET-1 level showed no correlation with serum creatinine, complement and anti-dsDNA(p>0.05).
    3) ET-1 clearance showed no significant correlaticn with creatinine clearance rate, complement anti-dsDNA ana urinlary NAG excretion.
    Plasma ET-1 level and its clearance rate could not reflect the lupus nephritis activity. But our study included small number of patients and only 2 patients of pathologically proven lupus nephritis showed active disease, biochemically and clinically, ana the majority of patients has alreday been in remission state after treatment. Above factors probably acted as a bias against the results, leading to statistical limitations. In further studies, we should broaden our subject group in number and to other renal diseases than limiting to lupus nephritis and prospective long term follow up study is indicated to further investigate the role of urinary excretion of ET-1 and their mechanism of action on renal disease.

Figure & Data

References

    Citations

    Citations to this article as recorded by  

      Download Citation

      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

      Format:

      Include:

      Endothelin-1 In Patients With Lupus Nephritis
      Ihwa Ŭidae chi. 1993;16(3):215-226.   Published online July 24, 2015
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Endothelin-1 In Patients With Lupus Nephritis
      Ihwa Ŭidae chi. 1993;16(3):215-226.   Published online July 24, 2015
      Close
      Endothelin-1 In Patients With Lupus Nephritis
      Endothelin-1 In Patients With Lupus Nephritis
      TOP